advanced non-small cell lung cancer with hemoptysis
Conditions
Interventions
experimental group:Gemcitabine loaded by CalliSpheres
control group:Gemcitabine implantation chemotherapy+8Spheres microsphere embolization
Sponsors
Affiliated Cancer Hospital of Chongqing University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years, patients with advanced non-small cell lung cancer combined with hemoptysis cannot be surgically removed or do not want to be surgically removed, with a pre-survival period of more than 12 weeks; 2. Non-small cell lung cancer was confirmed by pathological examination,TNM stage III or IV; 3. ECOG score = 90 g/L; (b) White blood cell (ANC) >= 1.5 x 10^9/L; (c) Platelet (PLT) >= 60 x 10^9/L; (2) biochemical examination: (a) albumin (ALB) >= 29 g/L; (b) ALT and AST <5ULN; Total bilirubin (TBIL) <= 50umol/L; Creatinine 1.5 or less ULN. 5. The patient and/or family members agree to participate in the clinical trial and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Recent pulmonary embolism (within 3 months); 2. Pregnancy and lactation; 3. Abnormal coagulation function (INR > 1.5 or prothrombin time (PT) > ULN+4 seconds), bleeding tendency or receiving thrombolysis or anticoagulant therapy; 4. Before enrollment, patients received molecular targeted drug therapy, radiotherapy, chemotherapy, etc. 5. Suffering from myocardial ischemia and myocardial infarction II class above, poor control of arrhythmia (including QTc interphase male 450, female 470 ms or ms or higher); 6. Patients with severe pulmonary dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemostatic efficacy;ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;PFS;TTUP;DCR;AE;QOL; | — |
Countries
China
Contacts
Public ContactXiao Jing
Affiliated Cancer Hospital of Chongqing University
Outcome results
None listed